FY2025 EPS Estimates for Biomea Fusion Decreased by Analyst

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities researchers at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Biomea Fusion in a research report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($3.91) for the year, down from their prior forecast of ($3.17). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($2.45) EPS.

Biomea Fusion (NASDAQ:BMEA) last announced its earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.19.

A number of other research analysts have also commented on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Biomea Fusion in a report on Wednesday, March 19th. Barclays lowered their price target on shares of Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a research report on Monday, March 24th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $23.91.

Biomea Fusion Stock Up 8.5 %

Shares of NASDAQ:BMEA opened at $2.16 on Thursday. The stock has a market cap of $78.28 million, a PE ratio of -0.54 and a beta of -0.26. Biomea Fusion has a 12-month low of $1.87 and a 12-month high of $14.43. The business has a 50 day moving average of $3.19 and a 200-day moving average of $5.89.

Hedge Funds Weigh In On Biomea Fusion

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC boosted its stake in Biomea Fusion by 0.7% in the third quarter. FMR LLC now owns 5,431,525 shares of the company’s stock valued at $54,858,000 after buying an additional 39,959 shares in the last quarter. Geode Capital Management LLC boosted its position in Biomea Fusion by 0.7% in the third quarter. Geode Capital Management LLC now owns 601,479 shares of the company’s stock valued at $6,076,000 after buying an additional 4,291 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Biomea Fusion by 104.4% during the fourth quarter. Two Sigma Investments LP now owns 559,930 shares of the company’s stock worth $2,173,000 after buying an additional 286,049 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Biomea Fusion by 290.7% in the 4th quarter. Two Sigma Advisers LP now owns 459,500 shares of the company’s stock valued at $1,783,000 after acquiring an additional 341,900 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Biomea Fusion by 317.7% during the 4th quarter. Renaissance Technologies LLC now owns 343,732 shares of the company’s stock valued at $1,334,000 after acquiring an additional 261,432 shares in the last quarter. Institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.